HC Wainwright Research Analysts Boost Earnings Estimates for ADMA Biologics, Inc. (NASDAQ:ADMA)

ADMA Biologics, Inc. (NASDAQ:ADMA) – Investment analysts at HC Wainwright lifted their Q3 2024 earnings estimates for shares of ADMA Biologics in a note issued to investors on Monday, August 12th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will earn $0.13 per share for the quarter, up from their prior forecast of $0.10. HC Wainwright currently has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for ADMA Biologics’ current full-year earnings is $0.35 per share. HC Wainwright also issued estimates for ADMA Biologics’ Q4 2024 earnings at $0.15 EPS, FY2024 earnings at $0.49 EPS, Q1 2025 earnings at $0.16 EPS, Q2 2025 earnings at $0.17 EPS, Q3 2025 earnings at $0.17 EPS, Q4 2025 earnings at $0.18 EPS and FY2025 earnings at $0.68 EPS.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.05. ADMA Biologics had a negative net margin of 1.29% and a positive return on equity of 17.24%. The firm had revenue of $107.20 million during the quarter, compared to analyst estimates of $86.44 million. During the same quarter in the prior year, the business posted ($0.02) EPS. The business’s revenue was up 78.4% compared to the same quarter last year.

Several other brokerages have also weighed in on ADMA. Mizuho lifted their price objective on ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, June 20th. Raymond James lifted their target price on shares of ADMA Biologics from $8.00 to $10.00 and gave the stock a “strong-buy” rating in a research note on Friday, May 10th. Finally, Cantor Fitzgerald upped their price target on shares of ADMA Biologics from $15.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, ADMA Biologics presently has a consensus rating of “Buy” and a consensus target price of $15.50.

ADMA Biologics Stock Performance

Shares of ADMA stock opened at $17.59 on Wednesday. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.86 and a current ratio of 5.21. The firm has a market cap of $4.08 billion, a price-to-earnings ratio of -879.50 and a beta of 0.55. ADMA Biologics has a 52 week low of $3.06 and a 52 week high of $17.87. The firm’s 50-day simple moving average is $12.32 and its two-hundred day simple moving average is $8.68.

Insider Buying and Selling

In related news, CEO Adam S. Grossman sold 100,000 shares of the company’s stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $10.72, for a total value of $1,072,000.00. Following the transaction, the chief executive officer now owns 2,081,475 shares in the company, valued at approximately $22,313,412. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 3.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ADMA Biologics

A number of hedge funds have recently added to or reduced their stakes in ADMA. Mesirow Institutional Investment Management Inc. purchased a new position in ADMA Biologics in the 1st quarter worth about $17,221,000. Bank of Montreal Can bought a new stake in shares of ADMA Biologics in the second quarter worth approximately $17,886,000. D. E. Shaw & Co. Inc. grew its stake in shares of ADMA Biologics by 26.8% in the second quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock worth $76,298,000 after acquiring an additional 1,442,799 shares during the period. Rice Hall James & Associates LLC purchased a new position in shares of ADMA Biologics during the first quarter valued at approximately $7,963,000. Finally, Castleark Management LLC bought a new position in ADMA Biologics during the first quarter valued at approximately $5,400,000. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.